Every 10-Q that Myriad Genetics Inc (MYGN) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow MYGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full MYGN filings page.
Myriad Genetics reported modest Q1 2026 revenue growth but a larger net loss. Revenue rose to $200.4 million from $195.9 million, driven by stronger Mental Health sales and higher Cancer Care Continuum volume, partially offset by lower Prenatal Health revenue.
The company posted a net loss of $34.1 million versus near breakeven a year ago, mainly due to the absence of a prior one-time tax benefit and a $5.4 million goodwill and long‑lived asset impairment. Operating loss was $30.7 million compared with $29.0 million. Cash and cash equivalents declined to $124.4 million from $149.6 million, with operating cash outflow of $15.7 million. Long‑term debt remained around $125.0 million under a SOFR‑based term loan maturing in 2030.
Myriad Genetics reported Q3 2025 results showing steady operations but ongoing losses. Revenue was $205.7 million versus $213.3 million a year ago, with gross profit of $143.8 million and an operating loss of $23.3 million. Net loss for the quarter was $27.4 million, or $0.29 per share.
Segment trends were mixed: Hereditary Cancer revenue rose to $93.0 million, Prenatal to $44.5 million, while Pharmacogenomics fell to $38.7 million, reflecting lower average revenue per test and payer coverage changes. Year‑to‑date, the company recorded $316.7 million of goodwill and intangible impairments, driving a YTD net loss of $358.0 million and reducing intangible balances.
Liquidity strengthened with cash and equivalents of $145.4 million. Long‑term debt increased to $119.5 million after a new $125.0 million secured term loan maturing in 2030 at an interest rate of about 10.8%. The facility includes monthly trailing 12‑month revenue covenants beginning at $615.0 million as of December 31, 2025. Net cash used in operations was $8.8 million year‑to‑date.